Literature DB >> 25049377

Type-I interferon signaling through ISGF3 complex is required for sustained Rip3 activation and necroptosis in macrophages.

Scott McComb1, Erin Cessford2, Norah A Alturki2, Julie Joseph2, Bojan Shutinoski2, Justyna B Startek3, Ana M Gamero4, Karen L Mossman5, Subash Sad6.   

Abstract

Myeloid cells play a critical role in perpetuating inflammation during various chronic diseases. Recently the death of macrophages through programmed necrosis (necroptosis) has emerged as an important mechanism in inflammation and pathology. We evaluated the mechanisms that lead to the induction of necrotic cell death in macrophages. Our results indicate that type I IFN (IFN-I) signaling is a predominant mechanism of necroptosis, because macrophages deficient in IFN-α receptor type I (IFNAR1) are highly resistant to necroptosis after stimulation with LPS, polyinosinic-polycytidylic acid, TNF-α, or IFN-β in the presence of caspase inhibitors. IFN-I-induced necroptosis occurred through both mechanisms dependent on and independent of Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) and led to persistent phosphorylation of receptor-interacting protein 3 (Rip3) kinase, which resulted in potent necroptosis. Although various IFN-regulatory factors (IRFs) facilitated the induction of necroptosis in response to IFN-β, IRF-9-STAT1- or -STAT2-deficient macrophages were highly resistant to necroptosis. Our results indicate that IFN-β-induced necroptosis of macrophages proceeds through tonic IFN-stimulated gene factor 3 (ISGF3) signaling, which leads to persistent expression of STAT1, STAT2, and IRF9. Induction of IFNAR1/Rip3-dependent necroptosis also resulted in potent inflammatory pathology in vivo. These results reveal how IFN-I mediates acute inflammation through macrophage necroptosis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25049377      PMCID: PMC4128105          DOI: 10.1073/pnas.1407068111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  51 in total

Review 1.  IRF family of transcription factors as regulators of host defense.

Authors:  T Taniguchi; K Ogasawara; A Takaoka; N Tanaka
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

3.  Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-β autocrine signaling to promote monocyte recruitment.

Authors:  Deepak Venkatesh; Thomas Ernandez; Florencia Rosetti; Ibrahim Batal; Xavier Cullere; Francis W Luscinskas; Yuzhi Zhang; George Stavrakis; Guillermo García-Cardeña; Bruce H Horwitz; Tanya N Mayadas
Journal:  Immunity       Date:  2013-04-25       Impact factor: 31.745

4.  Cathepsins limit macrophage necroptosis through cleavage of Rip1 kinase.

Authors:  Scott McComb; Bojan Shutinoski; Susan Thurston; Erin Cessford; Kriti Kumar; Subash Sad
Journal:  J Immunol       Date:  2014-05-05       Impact factor: 5.422

5.  Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis.

Authors:  Y Lin; A Devin; Y Rodriguez; Z G Liu
Journal:  Genes Dev       Date:  1999-10-01       Impact factor: 11.361

6.  Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction.

Authors:  M Sato; H Suemori; N Hata; M Asagiri; K Ogasawara; K Nakao; T Nakaya; M Katsuki; S Noguchi; N Tanaka; T Taniguchi
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

7.  Essential and non-redundant roles of p48 (ISGF3 gamma) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies.

Authors:  T Kimura; Y Kadokawa; H Harada; M Matsumoto; M Sato; Y Kashiwazaki; M Tarutani; R S Tan; T Takasugi; T Matsuyama; T W Mak; S Noguchi; T Taniguchi
Journal:  Genes Cells       Date:  1996-01       Impact factor: 1.891

8.  Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock.

Authors:  Jonas Sundén-Cullberg; Anna Norrby-Teglund; Ari Rouhiainen; Heikki Rauvala; Gunilla Herman; Kevin J Tracey; Martin L Lee; Jan Andersson; Leif Tokics; Carl Johan Treutiger
Journal:  Crit Care Med       Date:  2005-03       Impact factor: 7.598

9.  cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation.

Authors:  S McComb; H H Cheung; R G Korneluk; S Wang; L Krishnan; S Sad
Journal:  Cell Death Differ       Date:  2012-05-11       Impact factor: 15.828

10.  Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models.

Authors:  N Takahashi; L Duprez; S Grootjans; A Cauwels; W Nerinckx; J B DuHadaway; V Goossens; R Roelandt; F Van Hauwermeiren; C Libert; W Declercq; N Callewaert; G C Prendergast; A Degterev; J Yuan; P Vandenabeele
Journal:  Cell Death Dis       Date:  2012-11-29       Impact factor: 8.469

View more
  78 in total

Review 1.  Necroptosis: A new way of dying?

Authors:  Britt Hanson
Journal:  Cancer Biol Ther       Date:  2016-07-19       Impact factor: 4.742

Review 2.  Fight or flight: regulation of emergency hematopoiesis by pyroptosis and necroptosis.

Authors:  Ben A Croker; John Silke; Motti Gerlic
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

3.  Cell cycle arrest in mitosis promotes interferon-induced necroptosis.

Authors:  Tanja Frank; Marcel Tuppi; Manuela Hugle; Volker Dötsch; Sjoerd J L van Wijk; Simone Fulda
Journal:  Cell Death Differ       Date:  2019-02-11       Impact factor: 15.828

4.  Viral RNA at Two Stages of Reovirus Infection Is Required for the Induction of Necroptosis.

Authors:  Angela K Berger; Bradley E Hiller; Deepti Thete; Anthony J Snyder; Encarnacion Perez; Jason W Upton; Pranav Danthi
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

Review 5.  Host-Intrinsic Interferon Status in Infection and Immunity.

Authors:  Beiyun C Liu; Joseph Sarhan; Alexander Poltorak
Journal:  Trends Mol Med       Date:  2018-07-07       Impact factor: 11.951

Review 6.  Manipulation of apoptosis and necroptosis signaling by herpesviruses.

Authors:  Hongyan Guo; William J Kaiser; Edward S Mocarski
Journal:  Med Microbiol Immunol       Date:  2015-04-01       Impact factor: 3.402

7.  RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus.

Authors:  Shoko Nogusa; Roshan J Thapa; Christopher P Dillon; Swantje Liedmann; Thomas H Oguin; Justin P Ingram; Diego A Rodriguez; Rachelle Kosoff; Shalini Sharma; Oliver Sturm; Katherine Verbist; Peter J Gough; John Bertin; Boris M Hartmann; Stuart C Sealfon; William J Kaiser; Edward S Mocarski; Carolina B López; Paul G Thomas; Andrew Oberst; Douglas R Green; Siddharth Balachandran
Journal:  Cell Host Microbe       Date:  2016-06-16       Impact factor: 21.023

8.  The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis.

Authors:  Claudia Günther; Gui-Wei He; Andreas E Kremer; James M Murphy; Emma J Petrie; Kerstin Amann; Peter Vandenabeele; Andreas Linkermann; Christopher Poremba; Ulrike Schleicher; Christin Dewitz; Stefan Krautwald; Markus F Neurath; Christoph Becker; Stefan Wirtz
Journal:  J Clin Invest       Date:  2016-10-17       Impact factor: 14.808

9.  Intracellular Nucleic Acid Sensing Triggers Necroptosis through Synergistic Type I IFN and TNF Signaling.

Authors:  Michelle Brault; Tayla M Olsen; Jennifer Martinez; Daniel B Stetson; Andrew Oberst
Journal:  J Immunol       Date:  2018-03-14       Impact factor: 5.422

10.  Tristetraprolin regulates necroptosis during tonic Toll-like receptor 4 (TLR4) signaling in murine macrophages.

Authors:  Ardeshir Ariana; Norah A Alturki; Stephanie Hajjar; Deborah J Stumpo; Christopher Tiedje; Emad S Alnemri; Matthias Gaestel; Perry J Blackshear; Subash Sad
Journal:  J Biol Chem       Date:  2020-02-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.